Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Osteoporos Rep. 2012 Dec;10(4):248-50. doi: 10.1007/s11914-012-0116-1.

Osteoporosis treatment by a new active vitamin D3 compound, eldecalcitol, in Japan.

Author information

1
University of Tokushima Graduate School of Medical Sciences, Japan. toshimat@clin.med.tokushima-u.ac.jp

Abstract

Although vitamin D is used mainly as a nutritional supplement in osteoporosis treatment, its active form, 1,25-dihydroxyvitamin D [1,25(OH)(2)D], has an effect to maintain bone remodeling balance as well. Eldecalcitol is an analog of 1,25(OH) (2)D(3) with stronger effects than its native form in improving bone remodeling balance and increasing bone mineral density in osteoporotic patients. Daily 0.75 μg eldecalcitol is superior to 1.0 μg alfacalcidol in preventing new vertebral fractures under vitamin D supplementation, and is approved for osteoporosis treatment in Japan. Eldecalcitol also decreases wrist fractures. Further studies are warranted to examine the effect of eldecalcitol on other nonvertebral fractures, extraskeletal systems including falls, and combined treatment with other drugs in osteoporotic patients, as well as the mechanism of action of eldecalcitol.

PMID:
22918710
DOI:
10.1007/s11914-012-0116-1
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center